

Message

From: **Ex. 6 Personal Privacy (PP)**
Sent: 3/29/2021 11:38:09 AM
To: **Ex. 6 Personal Privacy (PP)**
CC: **Ex. 6 Personal Privacy (PP)** **Ex. 6 Personal Privacy (PP)**
Subject: RE: P-16-0180

Ex. 6 Personal Privacy (PP)

Will do...am copying **Ex. 6 Personal Privacy (PP)** (even though she is out) as the person who is on HoF duty for HH is in her branch (**Ex. 6 Personal Privacy (PP)**). Am also copying **Ex. 6 Personal Privacy (PP)**.

Regards,

Ex. 6 Personal Privacy (PP)

US EPA

Ex. 6 Personal Privacy (PP)

Office of Chemical Safety and Pollution Prevention (OCSP)
Office of Pollution Prevention and Toxics (OPPT)
New Chemicals Division (NCD)
1200 Pennsylvania Ave, NW
Washington, DC 20460

Ex. 6 Personal Privacy (PP)

From: **Ex. 6 Personal Privacy (PP)**

Sent: Monday, March 29, 2021 7:30 AM

To: **Ex. 6 Personal Privacy (PP)**

Cc: **Ex. 6 Personal Privacy (PP)**

Subject: Re: P-16-0180

Yes please move it up in the queue and let me know the projection of when it can be completed. I'll have a follow up discussion with Dow after I hear back from you.

Note: until we have **Ex. 5 Deliberative Process (DP)**

Ex. 5 Deliberative Process (DP)

Sent from my iPhone

On Mar 29, 2021, at 7:25 AM, **Ex. 6 Personal Privacy (PP)** wrote:

Ex. 6 Personal Privacy (PP) /All:

In my quick check it looks like it is not in management review and we need a new human health risk assessment; let me know how you would like me to prioritize this (I can assign it to the person on hair on fire call for this week....).

Regards,

Ex. 6 Personal Privacy (PP)

US EPA

Ex. 6 Personal Privacy (PP)

Office of Chemical Safety and Pollution Prevention (OCSPPP)

Office of Pollution Prevention and Toxics (OPPT)

New Chemicals Division (NCD)

1200 Pennsylvania Ave, NW

Washington, DC 20460

Ex. 6 Personal Privacy (PP)

From: Ex. 6 Personal Privacy (PP)

Sent: Monday, March 29, 2021 7:00 AM

To: Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

Cc: Ex. 6 Personal Privacy (PP)

Subject: RE: P-16-0180

Thanks, [REDACTED] Let me check with RAB and I'll get back to you. Likely, we can set up a call later this week.

[REDACTED] - can you let me know if this case is in management review queue and how much effort will it be to close it out?

Ex. 6 Personal Privacy (PP)

New Chemicals Division

USEPA/OCSPPP/OPPT

Ex. 6 Personal Privacy (PP)

From: Ex. 6 Personal Privacy (PP)

Sent: Thursday, March 25, 2021 6:08 PM

To: Ex. 6 Personal Privacy (PP)

Cc:

Subject: FW: P-16-0180

Hi [REDACTED] – I promised Kari that I would follow-up with you this week concerning the status of the above PMN. If you recall this PMN was also raised in a company meeting with you earlier this year. Engineering and exposure completed their updates in Sept/Oct 2020. I am still waiting for health to update the risk assessment based on those revisions. While I know we are in the process of prioritizing the review of PMNs beyond day 90 it would be helpful and probably appease them if I could provide an idea as to where their review is in the queue. Otherwise, she may request a meeting with you and/or elevate further. Please see the email chain below and advise as to our next steps. Thanks, enjoy your evening.

From: Mavian, Kari (K) <KMavian@dow.com>

Sent: Friday, March 19, 2021 3:10 PM

To:

Cc: **Ex. 6 Personal Privacy (PP)**

Subject: RE: P-16-0180

Thanks for the quick reply [REDACTED] Have a good weekend, and I look forward to an update next week!

Best,
Kari

From: **Ex. 6 Personal Privacy (PP)**

Sent: Friday, March 19, 2021 1:57 PM

To: Mavian, Kari (K) <KMavian@dow.com>

Cc: **Ex. 6 Personal Privacy (PP)**

Subject: RE: P-16-0180

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Kari – Thank you for your email. [REDACTED] is out of the office today and I will be out on Monday. You are correct in that there is not a hold or pause on PMN reviews and we are making every effort to prioritize and complete reviews as quickly as possible. We are currently balancing the transition of administrations, competing agency priorities, potential changes in policy and resource implications. However, effectively and efficiently reviewing PMNs remains our primary goal. I will speak with [REDACTED] next week to discuss the path forward for this case and provide you an update as soon as possible. Have a great weekend.

From: Mavian, Kari (K) <KMavian@dow.com>

Sent: Friday, March 19, 2021 11:15 AM

To: [REDACTED] Ex. 6 Personal Privacy (PP)

Subject: RE: P-16-0180

Hi [REDACTED] and [REDACTED]

I wanted to follow up on this PMN that has been pending since 2016. When we spoke with [REDACTED] back in January, it sounded like EPA had everything they needed to finish this up. We appreciate [REDACTED]'s updates, and I understand that we have just granted another 2 week extension.

I also understand from an ACC meeting with [REDACTED] Ex. 6 Personal Privacy (PP) on Monday that PMN reviews are not on a hold or pause. Is there a reason why this PMN continues to be held up? Can we do anything or provide any additional information to complete this review?

Thank you both for your attention to this.

Best regards,

Kari

Kari Mavian

Senior Government Affairs Director

Dow

500 North Capitol St NW, Suite 200, Washington, D.C. 20001
Mobile: 202.997.1613 | Email: kmavian@dow.com



From: [Ex. 6 Personal Privacy (PP)] >
Sent: Tuesday, January 12, 2021 4:31 PM
To: Mavian, Kari (K) <KMavian@dow.com>
Cc: [Ex. 6 Personal Privacy (PP)]
Subject: P-16-0180

Kari,

It was good to talk to you the other day.

As a follow up to your question on P-16-0180, please coordinate directly with [Ex. 6 Personal Privacy (PP)] (copied on this email). [] can provide you an update and provide next steps. Thanks.

[Ex. 6 Personal Privacy (PP)]

New Chemicals Division

USEPA/OCSP/OPPT

[Ex. 6 Personal Privacy (PP)]